Kostaki Maria, Manona Argyro D, Stavraka Irene, Korkolopoulou Penelope, Levidou Georgia, Trigka Eleni-Andriana, Christofidou Eleftheria, Champsas Grigorios, Stratigos Alexandros J, Katsambas Andreas, Papadopoulos Othon, Piperi Christina, Papavassiliou Athanasios G
Department of Biological Chemistry, University of Athens Medical School, Athens, Greece.
Exp Dermatol. 2014 May;23(5):332-8. doi: 10.1111/exd.12398.
Epigenetic mechanisms participate in melanoma development and progression. The effect of histone modifications and their catalysing enzymes over euchromatic promoter DNA methylation in melanoma remains unclear. This study investigated the potential association of p16(INK) (4A) promoter methylation with histone methyltransferase SETDB1 expression in Greek patients with sporadic melanoma and their correlation with clinicopathological characteristics. Promoter methylation was detected by methylation-specific PCR in 100 peripheral blood samples and 58 melanoma tissues from the same patients. Cell proliferation (Ki-67 index), p16(INK) (4A) and SETDB1 expression were evaluated by immunohistochemistry. High-frequency promoter methylation (25.86%) was observed in tissue samples and correlated with increased cell proliferation (P = 0.0514). p16(INK) (4A) promoter methylation was higher in vertical growth-phase (60%) melanomas than in radial (40%, P = 0.063) and those displaying epidermal involvement (P = 0.046). Importantly, p16(INK) (4A) methylation correlated with increased melanoma thickness according to Breslow index (P = 0.0495) and marginally with increased Clark level (I/II vs III/IV/V, P = 0.070). Low (1-30%) p16(INK) (4A) expression was detected at the majority (19 of 54) of melanoma cases (35.19%), being marginally correlated with tumor lymphocytic infiltration (P = 0.078). SETDB1 nuclear immunoreactivity was observed in 47 of 57 (82.46%) cases, whereas 27 of 57 (47.37%) showed cytoplasmic immunoexpression. Cytoplasmic SETDB1 expression correlated with higher frequency of p16(INK) (4A) methylation and p16(INK) (4A) expression (P = 0.033, P = 0.011, respectively). Increased nuclear SETDB1 levels were associated with higher mitotic count (0-5/mm(2) vs >5/mm(2) , P = 0.0869), advanced Clark level (III-V, P = 0.0380), epidermal involvement (P = 0.0331) and the non-chronic sun exposure-associated melanoma type (P = 0.0664). Our data demonstrate for the first time the association of histone methyltransferase SETDB1 with frequent methylation of the euchromatic p16(INK) (4A) promoter and several prognostic parameters in melanomas.
表观遗传机制参与黑色素瘤的发生和发展。组蛋白修饰及其催化酶对黑色素瘤常染色质启动子DNA甲基化的影响仍不清楚。本研究调查了希腊散发性黑色素瘤患者中p16(INK)(4A)启动子甲基化与组蛋白甲基转移酶SETDB1表达的潜在关联及其与临床病理特征的相关性。通过甲基化特异性PCR在100份外周血样本和来自同一患者的58份黑色素瘤组织中检测启动子甲基化。通过免疫组织化学评估细胞增殖(Ki-67指数)、p16(INK)(4A)和SETDB1表达。在组织样本中观察到高频启动子甲基化(25.86%),并与细胞增殖增加相关(P = 0.0514)。垂直生长期(60%)黑色素瘤的p16(INK)(4A)启动子甲基化高于放射状期(40%,P = 0.063)和有表皮受累的黑色素瘤(P = 0.046)。重要的是,根据Breslow指数,p16(INK)(4A)甲基化与黑色素瘤厚度增加相关(P = 0.0495),与Clark分级增加呈边缘相关(I/II级与III/IV/V级,P = 0.070)。在大多数(54例中的19例,35.19%)黑色素瘤病例中检测到低水平(1-30%)的p16(INK)(4A)表达,与肿瘤淋巴细胞浸润呈边缘相关(P = 0.078)。在57例中的47例(82.46%)观察到SETDB1核免疫反应性,而57例中的27例(47.37%)显示细胞质免疫表达。细胞质SETDB1表达与p16(INK)(4A)甲基化和p16(INK)(4A)表达的较高频率相关(分别为P = 0.033,P = 0.011)。核SETDB1水平升高与较高的有丝分裂计数(0-5/平方毫米 vs >5/平方毫米,P = 0.0869)、高级Clark分级(III-V级,P = 0.0380)、表皮受累(P = 0.0331)和非慢性阳光暴露相关的黑色素瘤类型(P = 0.0664)相关。我们的数据首次证明组蛋白甲基转移酶SETDB1与常染色质p16(INK)(4A)启动子的频繁甲基化以及黑色素瘤的几个预后参数有关。